<DOC>
	<DOCNO>NCT00077688</DOCNO>
	<brief_summary>Phase 2B , multicenter study evaluate safety efficacy weekly TOCOSOL Paclitaxel taxane-naive patient receive second line chemotherapy metastatic locally advanced , unresectable transitional cell carcinoma urothelium</brief_summary>
	<brief_title>TOCOSOL ( TM ) Paclitaxel Metastatic Locally Advanced Unresectable Transitional Cell Carcinoma Urothelium</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologic diagnosis transitional cell carcinoma ( TCC ) urothelium include bladder , renal pelvis , ureter , urethra Stage IV disease One one prior systemic cytotoxic chemotherapy regimen administer adjuvant neoadjuvant chemotherapy treat locally advance metastatic disease Adequate hematologic function ( ANC &gt; /= 1500 cells/mm3 &amp; platelet count &gt; /= 100,000/mm3 ) Serum creatinine &lt; /= 2.0 mg/dL Total bilirubin &lt; /= 1.5 mg/dL SGOT &amp; SGPT &lt; /= 3 time upper limit institutional normal value PT ( INR ) &amp; PTT within institutional lab normal range Karnofsky performance status 60100 % At least one unidimensionally measurable lesion , suitable radiographic evaluation disease response , consistent RECIST criterion Signed IRB/EC approve Informed Consent Life expectancy least 12 week 18 year age older Fully recover previous surgery Not pregnant willing use medically effective form contraception period chemotherapy treatment ( male female ) Agree take vitamin E supplementation receive study medication Willing participate request followup evaluation Willing permit treat physician provide information Sonus regard disease status survival 2 year first dose study drug Prior taxanecontaining chemotherapy include Taxol ( R ) ( paclitaxel ) generic equivalent , Taxotere ( R ) ( docetaxel ) Peripheral neuropathy NCICTC grade 2 great Widefield radiation , cytotoxic chemotherapy hormonal therapy within 4 week first dose , mitomycin nitrosoureas within 6 week first dose , study drug An investigational agent within 4 week first dose study drug Concurrent anticonvulsant know induce P450 isoenzymes Patients pregnant lactate A history carcinoma another primary site ( nonmelanoma skin cancer carcinomainsitu cervix ) within previous 5 year , unless metastatic disease biopsied documented TCC Bone metastasis , effusion , ascites elevate tumor marker evidence metastatic TCC Brain metastasis Active bowel obstruction Active , serious infection serious medical problem ( TCC ) likely impair completion study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>